

研究成果の刊行に関する一覧表レイアウト（参考）

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
(分担) 考藤達哉	国の肝炎および肝がん対策	一般社団法人 日本肝臓学会	肝がん白書	日本印刷	東京	2022	44-47
(分担) 田中純子	わが国における肝癌の動向	一般社団法人 日本肝臓学会	肝がん白書	日本印刷	東京	2022	8-14
西井正造、 武部貴則	ストリート・メディカルとは？	井上 祥	医療者のための 情報発信	中外医学社	日本	2022	109-111

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Mino M, Kakazu E, Sano A, Katsuyama H, Hakoshima M, Yanai H, Aoki Y, Imamura M, Yamazoe T, Mori T, Yoshio S, Inoue J, Masamune A, <u>Kanto I.</u>	Effects on sodium glucose cotransporter 2 inhibitors and pioglitazone on FIB-4 index in metabolic-associated fatty liver disease.	<i>Hepatol Res.</i>			2023
Shimakami T, Setoyama H, Oza N, Itakura J, Kaneko S, Korenaga M, Toyama T, Tanaka J, <u>Kanto T*</u> .	Development of performance indicators for hepatitis countermeasures as a tool for the assessment and promotion of liver cancer prevention in Japan.	<i>J Gastroenterol</i>	58	257-267	2023
Kuramoto J, Arai E, Fujimoto M, Tian Y, Yamada Y, Yotani T, Makiuchi S, Tsuda N, Ojima H, Fukai M, Seki Y, Kasama K, Funahashi N, Udagawa H, Nammo T, Yasuda K, Taketomi A, <u>Kanto T</u> , Kanai Y.	Quantification of DNA methylation for carcinogenic risk estimation in patients with non-alcoholic steatohepatitis.	<i>Clin Epigenetics.</i>	14	168	2022

Kawai H, Osawa Y, Tsunoda T, Matsuda M, Okawara M, Sakamoto Y, Shimagaki T, Tsutsui Y, Yoshida Y, Yoshikawa S, Doi H, Mori T, Yamazoe T, Yoshio S, Okamura T, Sugiyama M, Okuzaki D, Komatsu H, Inui A, Yanaga K, Ikegami T, <u>Kanto T.</u>	Peripheral-dominant liver fibrosis and tumor distribution in a mouse model of congestive hepatopathy.	<i>Hepatol Res</i>	53	370-376	2022
Terahara K, Li TC, Matsubayashi K, Sakata H, Kato T, Naganuma A, Ogawa K, Honda K, Itakura J, Akutsu N, Tobita H, Korenaga M, <u>Kanto T.</u> , Sugiyama R, Suzuki R, Hamaguchi I, Isogawa M, Takahashi Y.	Calibrating hepatitis E virus serological assays using asymptomatic specimens obtained in Japan.	<i>Microbiol Spectr.</i>	10	e0214622	2022
Tsutsui Y, Yoshio S, Tomiyama T, Shimagaki T, Itoh S, Harada N, Yoshida Y, Yoshikawa S, Kakazu E, <u>Kanto T.</u> , Yoshizumi T.	Preoperative serum brain-derived neurotrophic factor as a predictive biomarker for sepsis after living-donor liver transplantation.	<i>Hepatol Res.</i>	53	72-83	2023
Korenaga M, Murata K, Izumi N, Tamaki N, Yokosuka O, Takehara T, Sakamoto N, Suda G, Nishiguchi S, Enomoto H, Ikeda F, Yanase M, Toyoda H, Genda T, Umemura T, Yatsuhashi H, Yamasaki K, Ide T, Toda N, Kanda T, Nirei K, Ueno Y, Haga H, Nishigaki Y, Nakane K, Omata M, Mochizuki H, Aoki Y, Imamura M, <u>Kanto T.</u> , Mizokami M.	No increased risk of hepatocellular carcinoma after eradication of hepatitis C virus by direct-acting antivirals, compared with interferon-based therapy.	<i>Glob Health Med.</i>	4	216-224	2022

Hussain MRA, Hiebert L, Sugiyama A, Ouoba S, Bunthen E, Ko K, Akita T, Kaneko S, <u>Kanto T</u> , Ward JW, Tanaka J.	Effect of COVID-19 on hepatitis B and C virus countermeasures: Hepatologist responses from nationwide survey in Japan.	<i>Hepatol Res</i>	52	899-907	2022
Kimura M, Nishikawa K, Osawa Y, Imamura J, Yamaji K, Harada K, Yatsuhashi H, Murata K, Miura K, Tanaka A, <u>Kanto T</u> , Kohara M, Kamisawa T, Kimura K.	Inhibition of CBP/ β -catenin signaling ameliorated fibrosis in cholestatic liver disease.	<i>Hepatol Commun</i>	6	1732-2747	2022
Okushin K, Tateishi R, Takahashi A, Uchino K, Nakagomi R, Nakatsuka T, Minami T, Sato M, Fujishiro M, Hasegawa K, Eguchi Y, <u>Kanto T</u> , Kubo S, Yoshiji H, Miyata H, Izumi N, Kudo M, Koike K.	Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL)	<i>J Gastroenterol</i>	57	587-597	2022
Tanaka J, Kurisu A, Ohara M, Ouoba S, Ohisa M, Sugiyama A, Wang ML, Hiebert L, <u>Kanto T</u> , Akita T.	Burden of chronic hepatitis B and C infections in 2015 and future trends in Japan: A simulation study.	<i>Lancet Reg Health West Pac</i>	22	100428	2022
Kimura K, <u>Kanto T</u> , Shimoda S, Harada K, Kimura M, Nishikawa K, Imamura J, Ogawa E, Saio M, Ikura Y, Okusaka T, Inoue K, Ishikawa T, Ieiri I, Kishimoto J, Todaka K, Kamisawa T.	Safety, tolerability, and anti-fibrotic efficacy of the CBP/ β -catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study.	<i>EBioMedicine</i> .	80	1-14	2022
Kaneko S, Kurosaki M, Kurisu A, Akita T, Tanaka J, <u>Kanto T</u> .	Impact of antiviral therapy for disease progression and non-invasive liver fibrosis index in patients with chronic hepatitis C: Markov chain model analysis.	<i>Hepatol Res</i> .	52	665-676	2022

Zhang H, Itoh Y, Suzuki T, Ihara KI, Tanaka T, Haga S, Enatsu H, Yumiya M, Kimura M, Takada A, Itoh D, Shibazaki Y, Nakao S, Yoshio S, Miyakawa K, Miyamoto Y, Sasaki H, Kajita T, Sugiyama M, Mizokami M, Tachibana T, Ryo A, Moriishi K, Miyoshi E, <u>Kanto T</u> , Okamoto T, Matsuura Y.	Establishment of monoclonal antibodies broadly neutralize infection of hepatitis B virus.	<i>Microbiol Immunol.</i>	66	179-192	2022
Tahata Y, Hikita H, Mochida S, Enomoto N, Kawada N, Kurosaki M, Ido A, Miki D, Yoshiji H, Takikawa Y, Sakamori R, Hiasa Y, Nakao K, Kato N, Ueno Y, Yatsushashi H, Itoh Y, Tateishi R, Suda G, Takami T, Nakamoto Y, Asahina Y, Matsuura K, Yamashita T, <u>Kanto I</u> , Akuta N, Terai S, Shimizu M, Sobue S, Miyaki T, Moriuchi A, Yamada R, Kodama T, Tatsumi T, Yamada T, Takehara T.	Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis	<i>J Gastroenterol.</i>	57	120-132	2022
Kawai H, Osawa Y, Mtasuda M, Tsunoda T, Yanagida K, Hishikawa D, Okawara M, Sakamoto Y, Shimagaki T, Tsutsui Y, Yoshida Y, Yoshikawa S, Hashi K, Doi H, Mori	Sphingosine-1-phosphate promotes tumor development and liver fibrosis in mouse model of congestive hepatopathy.	<i>Hepatology</i>	76	112-125	2022

Shinoda H, Watanabe Y, Fukai K, Kasuya K, Furuya Y, Nakazawa S, Honda T, Hayashi T, Nakagawa T, Tatemichi M, <u>Korenaga M.</u>	Significance of Fib4 index as an indicator of alcoholic hepatotoxicity in health examinations among Japanese male workers: a cross-sectional and retrospectively longitudinal study.	<i>Eur J Med Res.</i>	28	31	2023
Nakazawa S, Fukai K, Furuya Y, Hoshi K, Kojimahara N, Toyota A, <u>Korenaga M.</u> , Tatemichi M	Occupational class and risk for hepatitis B and C viral infection.	<i>J Infect Public Health.</i>	15	1415-1426	2022
<u>Shimakami T.</u> , Setoyama H, Oza N, Itakura J, Kaneko S, Korenaga M, Toyama T, Tanaka J, Kanto T.	Development of performance indicators for hepatitis countermeasures as a tool for the assessment and promotion of liver cancer prevention in Japan	<i>J Gastroenterol</i>	58(3)	257-267	2023
Sumiyadorj A, Murai K, <u>Shimakami T.</u> , Kuroki K, Nishikawa T, Kakuya M, Yamada A, Wang Y, Ishida A, Shirasaki T, Kawase S, Li YY, Okada H, Nio K, Kawaguchi K, Yamashita T, Sakai Y, Duger D, Mizukoshi E, Honda M, Kaneko S.	A single hepatitis B virus genome with a reporter allows the entire viral life cycle to be monitored in primary human hepatocytes.	<i>Hepatol Commun</i>	6(9)	2441-2454	2022
Li YY, Kuroki K, <u>Shimakami T.</u> , Murai K, Kawaguchi K, Shirasaki T, Nio K, Sugimoto S, Nishikawa T, Okada H, Orita N, Takayama H, Wang Y, Thi Bich PD, Ishida A, Iwabuchi S, Hashimoto S, Shimaoka T, Tabata N, Watanabe-Takahashi M, Nishikawa K, Yanagawa H, Seiki M, Matsushima K, Yamashita T, Kaneko S, Honda M.	Hepatitis B virus utilizes a retrograde trafficking route via the trans-Golgi network to avoid lysosomal degradation.	<i>Cell Mol Gastroenterol Hepatol</i>	15(3)	533-558	2022

Shirasaki T, Yamagoe S, <u>Shimakami T</u> , Murai K, Imamura R, Ishii KA, Takayama H, Matsumoto Y, Tajima-Shirasaki N, Nagata N, Shimizu R, Yamanaka S, Abe A, Omura H, Kawaguchi K, Okada H, Yamashita T, Yoshikawa T, Takimoto K, Taharaguchi M, Takatsuka S, Miyazaki Y, Tamai T, Tanabe Y, Kurachi M, Yamamoto Y, Kaneko S, Matsumoto K, Takamura T, Honda M.	Leukocyte cell-derived chemotaxin 2 is an antiviral regulator acting through the proto-oncogene MET	Nat Commun	13(1)	3176	2022
武部貴則、 <u>西井正造</u>	新しい医療を築く「スト リートメディカル」の発 想	医療福祉建築	218	14 - 15	2023
佐藤大樹, 出口亮, 小林洋平, 渡辺広道, 大迫真里子, 片岡公 一, 鈴木伸治, 秋 元康幸, <u>西井正造</u> , 武部貴則.	建設作業所と公共の場で のウェルビーイングに寄 与する空間の探索	アーバンインフ ラ・テクノロジー 推進会議	第34回技術 研究発表会		2022
佐藤大樹, 出口亮, 小林洋平, 渡辺広道, 大迫真里子, 片岡公 一, 鈴木伸治, 秋元 康幸, <u>西井正造</u> , 武 部貴則.	ウェルビーイングの向上 に寄与する建築・まちづ くりに関する研究	大成建設技術セ ンター報	55	2	2022
<u>西井正造</u> 、武部貴則	イネープリング・ファク ターとこれからの病院像	病院設備	64	14 - 17	2022

Keitoku T, <u>Tamaki N</u> , Kurosaki M, Inada K, Kirino S, Uchihara N, Suzuki K, Tanaka Y, Miyamoto H, Ishido S, Yamada M, Nobusawa T, Matsumoto H, Higuchi M, Takaura K, Tanaka S, Maeyashiki C, Kaneko S, Yasui Y, Takahashi Y, Tsuchiya K, Nakanishi H, Asahina Y, Okamoto R, Izumi N.	Effect of fatty liver and fibrosis on hepatocellular carcinoma development in patients with chronic hepatitis B who received nucleic acid analog therapy	<i>J Viral Hepat</i>	30	297-302	2023
Huang DQ, <u>Tamaki N</u> , Lee HW, Park SY, Lee YR, Lee HW, Lim SG, Lim TS, Kurosaki M, Marusawa H, Mashiba T, Kondo M, Uchida Y, Kobashi H, Furuta K, Izumi N, Kim BK, Sinn DH	Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis	<i>Hepatology</i>	77	1746-1756	2023
Kaneko S, Kurosaki M, Mashiba T, Marusawa H, Kondo M, Kojima Y, Uchida Y, Fujii H, Akahane T, Yagisawa H, Kusakabe A, Kobashi H, Abe T, Yoshida H, Ogawa C, Furuta K, <u>Tamaki N</u> , Tsuji K, Matsushita T, Izumi N; Japanese Red Cross Liver Study Group.	Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B	<i>J Med Virol</i>	95	e28210.	2023

Kirino S, <u>Tamaki N</u> , Kurosaki M, Kaneko S, Inada K, Tanaka Y, Ishido S, Yamashita K, Nobusawa T, Matsumoto H, Hayakawa Y, Kakegawa T, Higuchi M, Takaura K, Tanaka S, Maeyashiki C, Yasui Y, Takahashi Y, Tsuchiya K, Nakanishi H, Okamoto R, Izumi N.	Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analog therapy in patient with chronic hepatitis B	<i>Hepatol Res</i>	53	35-42	2023
Tada T, Kurosaki M, <u>Tamaki N</u> , Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H, Fujii H, Ishii T, Marusawa H, Kondo M, Kojima Y, Yoshida H, Uchida Y, Nakamura S, Izumi N.	General evaluation score for predicting the development of hepatocellular carcinoma in patients with advanced liver fibrosis associated with hepatitis C virus genotype 1 or 2 after direct-acting antiviral therapy	<i>JGH Open</i>	8	487-495	2022
Tan DJH, Ng CH, Tay PWL, Syn N, Muthiah MD, Lim WH, Tang ASP, Lim KE, Lim GEH, <u>Tamaki N</u> , Kim BK, Teng MLP, Fung J, Loomba R, Nguyen MH, Huang DQ	Risk of Hepatocellular Carcinoma with Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus: A Reconstructed Individual Patient Data Meta-analysis	<i>JAMA Netw Open</i>	5	e2219407	2022
Tokunaga T, Tateyama M, Kondo Y, Miura S, Miyase S, Tanaka K, Narahara S, Inada H, Kurano S, Yoshimaru Y, Nagaoka K, Watanabe T, <u>Setoyama H</u> , Fukubayashi K, Tanaka M, Tanaka Y	Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.	<i>Cancers</i>	15	1568	2023

Narahara S, Watanabe T, Nagaoka K, Fujimoto N, Furuta Y, Tanaka K, Tokunaga T, Kawasaki T, Yoshimaru Y, <u>Setoyama H</u> , Oniki K, Saruwatari J, Tateyama M, Naoe H, Tanaka M, Tanaka Y, Sasaki Y	Clusterin and Related Scoring Index as Potential Early Predictors of Response to Sorafenib in Hepatocellular Carcinoma.	<i>Hepatology Communications</i>	6	1198-1212	2022
Matsuno K, Miyamoto H, Kitada H, Yoshimatsu S, Tamura F, Sakurai K, Fukubayashi K, Shono T, <u>Setoyama H</u> , Matsuyama T, Suko S, Narita R, Honda M, Tateyama M, Naoe H, Morinaga J, Tanaka Y, Gushima R	Comparison of endoscopic submucosal resection with ligation and endoscopic submucosal dissection for small rectal neuroendocrine tumors: A multicenter retrospective study.	<i>DEN Open</i>	3	E163	2022
Imajo K, Toyoda H, Yasuda S, Suzuki Y, Sugimoto K, Kuroda H, Akita T, <u>Tanaka J</u> , Yasui Y, Tamaki N, Kurosaki M, Izumi N, Nakajima A, Kumada T	Utility of ultrasound-guided attenuation parameter for grading steatosis with reference to MRI-PDFF in a large cohort	Clinical gastroenterology and hepatology			In press
Ichikawa H, Yasuda E, Kumada T, Takeshima K, Ogawa S, Tsunekawa A, Goto T, Nakaya K, Akita T, <u>Tanaka J</u>	Intra-individual comparison of liver stiffness measurements by magnetic resonance elastography and two-dimensional shear-wave elastography in 888 patients	Ultrasonography	42(1)	65-77	2023
Toyoda H, Yasuda S, Shiota S, Kumada T, <u>Tanaka J</u>	Adherence to regular surveillance visits for hepatocellular carcinoma in patients with chronic hepatitis C virus infection who achieved sustained virologic response	European Journal of Gastroenterology and Hepatology	34(6)	693-697	2022
Sugiyama A, Kurisu A, Akita T, <u>Tanaka J</u>	Authors' response to "prevalence and incidence of fatty liver for people who took part in a health checkup in 2008-2019 in Japan"	Liver International	42(6)	1478	2022

Tada T, Kumada T, Matono T, Nakamura S, Sue M, Matuo Y, Masahiro T, Iijima H, <u>Tanaka J</u>	Characteristics of hepatocellular carcinoma in patients with hepatitis C virus who received direct-acting antiviral therapy and achieved sustained virological response: The impact of a hepatologist on surveillance	Journal of gastroenterology and hepatology open	6(7)	462-469	2022
Kumada T, Toyoda H, Yasuda S, Ogawa S, Gotoh T, Tada T, Ito T, Sumida Y, <u>Tanaka J</u>	Combined ultrasound and magnetic resonance elastography predict hepatocellular carcinoma after hepatitis C virus eradication	Hepatology Research	52(11)	957-967	2022
Sugiyama A, Kurisu A, E B, Ouoba S, Ko K, Rakhimov A, Akita T, Harakawa T, Sako T, Koshiyama M, Kumada T, <u>Tanaka J</u>	Distribution of FIB-4 index in the general population - Analysis of 75,666 residents who underwent health checkups-	BMC gastroenterology	22(1)	241	2022
Hussain Md RA, Hiebert L, Sugiyama A, Ouoba S, Bunthen E, Ko K, Akita T, Kaneko S, <u>Kanto T</u> , Ward JW, <u>Tanaka J</u>	Effect of COVID-19 on hepatitis B and C virus countermeasures: Hepatologist responses from nationwide survey in Japan	Hepatology Research	52(11)	899-907	2022
Kumada T, Toyoda H, Yasuda S, Ito T, Tsuji K, Fujioka S, Hiraoka A, Kariyama K, Nouse K, Ishikawa T, Tamai T, Tada T, <u>Tanaka J</u>	Factors linked to hepatocellular carcinoma development beyond 10 years after viral eradication in patients with hepatitis C virus	Journal of Viral Hepatitis	29(10)	919-929	2022
Blach S et al. (<u>Tanaka J</u> 259人中6番目)	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study	The LANCET Gastroenterology and Hepatology	7(5)	396-415	2022
Toyoda H, Yasuda S, Shiota S, Sone Y, Maeda A, Kaneoka Y, Kumada T, <u>Tanaka J</u>	Identification of the suitable candidates for EOB-MRI with the high risk of the presence of non-hypervascular hypointense nodules in patients with HCV infection	European Radiology	32(7)	5016-5023	2022

Kaneko S, Kurosaki M, Kurisu A, Akita T, Tanaka J, Kanto T	Impact of antiviral therapy for disease progression and non-invasive liver fibrosis index in patients with chronic hepatitis C: Markov chain model analysis	Hepatology Research	52(8)	665-676	2022
El-Ekiaby M, Tanaka J, van Drimmelen H, Allain JP, Lelie N	Infectivity of hepatitis B virus (HBV) surface antigen (HBsAg) positive plasma with undetectable HBV-DNA: Can HBsAg screening be discontinued in Egyptian blood donors?	Journal of Viral Hepatitis	29(5)	330-339	2022
Kumada T, Ogawa S, Goto T, Toyoda H, Yasuda S, Ito T, Yasuda E, Akita T, Tanaka J	Intra-individual comparisons of the ultrasound-guided attenuation parameter and the magnetic resonance imaging-based proton density fat fraction using bias and precision statistics	Ultrasound in Medicine and Biology	48(8)	1537-1546	2022
Kumada T, Toyoda H, Yasuda S, Ogawa S, Gotoh T, Ito T, Tada T, Tanaka J	Liver stiffness measurements by 2D shear-wave elastography: Effect of steatosis on fibrosis evaluation	American journal of roentgenology	219(4)	604-612	2022
Toyoda H, Yasuda S, Moriya A, Itobayashi E, Uojima H, Watanabe T, Atsukawa M, Arai T, Ishikawa T, Mikami S, Hiraoka A, Tsuji K, Oikawa T, Tsubota A, Nozaki A, Chuma M, Abe H, Shima T, Kumada T, Tanaka J	Misunderstanding of hepatitis C virus (HCV) infection status by non-specialized medical doctors in patients who achieved sustained virologic response to anti-HCV therapy	Journal of Infection and Chemotherapy	28(9)	1231-1234	2022
E B, Ou P, Ouoba S, Hussain Md RA, Ko K, Nagashima S, Sugiyama A, Akita T, Tanaka J	Prevalence and genotype distribution of viral hepatitis B in Cambodia between 1990 and 2020: A Systematic Review and Meta-analysis	Archives of Public Health	80(1)	119	2022

Nagaoki Y, Sugiyama A, Mino M, Kodama H, Abe K, Imada H, Ouoba S, E B, Ko K, Akita T, Sako T, Kumada T, Chayama K, <u>Tanaka J</u>	Prevalence of fatty liver and advanced fibrosis by ultrasonography and FibroScan in a general population random sample	Hepatology Research	52(11)	908-918	2022
Hayes NC, Imamura M, <u>Tanaka J</u> , Chayama K	Road to elimination of HCV: Clinical challenges in HCV management	Liver International	42(9)	1935-1944	2022
Toyoda H, Atsukawa M, Uojima H, Nozaki A, Takaguchi K, Hiraoka A, Itobayashi E, Watanabe T, Matsuura K, Shimada N, Abe H, Tsuji K, Itokawa N, Mikami S, Ishikawa T, Oikawa T, Yasuda S, Chuma M, <u>Tanaka J</u>	The Impact of cirrhosis and history of hepatocellular carcinoma on all-cause mortality after eradication of hepatitis C virus in patients with chronic hepatitis C	Gastro Hep Advances	1(4)	508	2022
<u>Tanaka J</u> , Kurisu A, Ohara M, Ouoba S, Ohisa M, Sugiyama A, Wang ML, Hiebert L, <u>Kanto T</u> , Akita T	Burden of chronic hepatitis B and C infections in 2015 and future trends in Japan: A simulation study	The Lancet regional health. Western Pacific	22()	100428	2022
Kikuchi M, Sawabe M, Aoyagi H, Wakae K, Watashi K, Hattori S, Kawabe N, Yoshikawa K, <u>Tanaka J</u> , Muramatsu M, Wakita T, Aizaki H	Development of an intervention system for linkage-to-care and follow-up for hepatitis B and C virus carriers	Hepatology International	16(1)	68-80	2022
Kumada T, Toyoda H, Yasuda S, Ito T, <u>Tanaka J</u>	Mortality of inactive hepatitis B virus carriers in Japan is similar to that of the general population	Hepatology Research	52(1)	81-92	2022
瀬戸山博子、考藤達哉	HCV撲滅に向けた医療行政の整備	肝臓	62巻4号	220-222	2021
瀬戸山博子、島上哲朗、考藤達哉	日本における肝炎総合対策	Medical Science Digest	14	716-719	2021
瀬戸山博子、考藤達哉	C型肝炎の行政対策	消化器内科	3巻7号	86-94	2021

Kawai H, Osawa Y, Mtasuda M, Tsunoda T, Yanagida K, Hishikawa D, Okawara M, Sakamoto Y, Shimagaki T, Tsutsui Y, Yoshida Y, Yoshikawa S, Hashi K, Doi H, Mori T, Yamazoe T, Yoshio S, Sugiyama M, Okuzaki D, Komatsu H, Inui A, Tamura-Nakano M, Oyama C, Shindou H, Kusano H, Kage M, Ikegami T, Yanaga K, <u>Kanto T*</u> .	Sphingosine-1-phosphate promotes tumor development and liver fibrosis in mouse model of congestive hepatopathy	Hepatology			2021 in press
Ishizaka A, Koga M, Mizutani T, Lim LA, Adachi E, Ikeuchi K, Ueda R, Aoyagi H, Tanaka S, Kiyono H, Matano T, Aizaki H, Yoshio S, Mita E, Muramatsu M, <u>Kanto T</u> , Tsutsumi T, Yotsuyanagi H.	Prolonged Gut Dysbiosis and Fecal Excretion of Hepatitis A Virus in Patients Infected with Human Immunodeficiency Virus	Viruses	13(10):2101. doi: 10.3390/v13102101.		2021
<u>Kanto T</u>	Messages from Japan policy for viral hepatitis	Global Health & Medicine	3(5)	249-252	2021
Takeuchi Y, Ohara M and <u>Kanto T*</u> .	Nationwide awareness-raising program for viral hepatitis in Japan: the “Shitte kan-en” project.	Global Health & Medicine	3(5)	301-307.	2021
Setoyama H, Tanaka Y and <u>Kanto T*</u> .	Seamless support from screening to anti-HCV treatment and HCC/decompensated cirrhosis: Subsidy programs for HCV elimination.	Global Health & Medicine	3(5)	335-342	2021
Korenaga M and <u>Kanto T*</u>	Testing, diagnosis of viral hepatitis, and the follow-up policy in Japan.	Global Health & Medicine	3(5)	308-313	2021
Doi H and <u>Kanto T*</u>	Factors influencing the durability of hepatitis B vaccine responses.	Vaccine:	39(36)	5224-5230	2021

Yoshida Y, Yoshio S*, Yamazoe T, Mori T, Tsustui Y, Kawai H, Yoshikawa S, Fukuhara T, Okamoto T, Ono Y, Takahashi Y, Hashida R, Kawaguchi T, Taketomi A, Kanto T.*	Phenotypic Characterization by Single-Cell Mass Cytometry of Human Intrahepatic and Peripheral NK Cells in Patients with Hepatocellular Carcinoma	Cells	10(6)	1495 doi: 10.3390/cells10061495.	2021
Yoshio S, Shimagaki T, Hashida R, Kawaguchi T, Tsutsui Y, Sakamoto Y, Yoshida Y, Kawai H, Yoshikawa S, Yamazoe T, Mori T, Osawa Y, Itoh S, Fukai M, Yoshizumi T, Taketomi A, Mori M, Kanto T.*	Myostatin as a fibroblast-activating factor impacts on postoperative outcome in patients with hepatocellular carcinoma.	Hepatol Res.	51(7)	803-812	2021
Osawa, Y; Kawai, H; Tsunoda, T; Komatsu, H; Okawara, M; Tsutsui, Y; Yoshida, Y; Yoshikawa, S; Mori, T; Yamazoe, T; Yoshio, S; Oide, T; Inui, A; Kanto, T.*	Cluster of differentiation 44 promotes liver fibrosis and serves as a biomarker in congestive hepatopathy.	Hepatol. Commun.	5(8)	1437-1447	2021
Itakura, J; Kurosaki, M; Setoyama, H; Simakami, T; Oza, N; Korenaga, M; Tanaka, M; Torimura, T; Sakamoto, N; Enomoto, N; Ueno, Y; Kawada, N; Kaneko, S; Nishiguchi, S; Chayama, K; Tanaka, J; Izumi, N; Kanto, T.	Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis.	J. Gastroenterol.	56	470-478	2021

Sakamoto Y, Yoshio S, Doi H, Mori T, Matsuda M, Kawai H, Shimagaki T, Yoshikawa S, Aoki Y, Osawa Y, Yoshida Y, Arai T, Itokawa N, Atsukawa M, Ito T, Honda T, Mise Y, Ono Y, Takahashi Y, Saiura A, Taketomi A, Kanto T* .	Increased frequency of dysfunctional Siglec-7-CD57+PD-1+ natural killer cells in patients with non-alcoholic fatty liver disease.	Frontiers Immunology	12	603133	2021
Osawa Y, Yoshio S, Aoki Y, Korenaga M, Imamura M, Oide T, Okawara M, Kawai H, Tsutsui Y, Yoshida Y, Yoshikawa S, Mori T, Yamazoe T, Kanto T* .	Blood angiopoietin-2 predicts liver angiogenesis and fibrosis in hepatitis C patients.	BMC Gastroenterol.	21(1):55.	doi: 10.1186/s12876-021-01633-8.	2021
Yoshio S and Kanto T* .	Macrophages as a source of fibrosis biomarkers for non-alcoholic fatty liver disease.	Immunological Medicine	14	1-26	2021
Yoshikawa S, Yoshio S, Yoshida Y, Tsutsui Y, Kawai H, Yamazoe T, Mori T, Osawa Y, Sugiyama M, Iwamoto M, Watashi K, Kawaguchi T, Akita T, Tanaka J , Kikuchi Y, Mizokami M, Oka S, Kanto T , Gatanaga H	Impact of immune reconstitution-induced hepatic flare on HBsAg loss in HBV/HIV-1-coinfected patients,	The Journal of Infectious Diseases	223(12)	2080-2089	2021
Matsugu Y, Ito K, Oshita A, Nobuhara H, Tanaka J , Akita T, Itamoto T	Postoperative oral energy and protein intakes for an enhanced recovery after surgery program incorporating early enteral nutrition for pancreaticoduodenectomy: A retrospective study	Nutrition in Clinical Practice			in press
Hayes NC, Imamura M, Tanaka J , Chayama K	Road to elimination of HCV: Clinical challenges in HCV management	Liver International			in press

The Polaris Observatory HCV Collaborators, Sarah Blach, Norah A Terrault, Frank Tacke, Ivane Gamkrelidze, Antonio Craxi, <u>Junko Tanaka</u> (6 番目)	Global change in hepatitis C virus prevalence as a cascade of care between 2015 and 2020: a modelling study	<i>The LANCET Gastroenterology and Hepatology</i>			in press
Toyoda H, Yasuda S, Shiota S, Kumada T, <u>Tanaka J</u>	Adherence to regular surveillance visits for hepatocellular carcinoma in patients with chronic hepatitis C virus infection who achieved sustained virologic response	<i>European Journal of Gastroenterology and Hepatology</i>			in press
Kitagawa H, Kaiki Y, Sugiyama A, Ngashima S, Kurisu A, Nomura T, Omori K, Akita T, Shigemoto N, <u>Tanaka J</u> , Ohge H	Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan	<i>Journal of infection and chemotherapy</i>			in press
Toyoda H, Yasuda S, Shiota S, Sone Y, Maeda A, Kaneoka Y, Kumada T, <u>Tanaka J</u>	Identification of the suitable candidates for EOB-MRI with the high risk of the presence of non-hypervascular hypointense nodules in patients with HCV infection	<i>European Radiology</i>			in press
Manry J, et al. (Tanaka J 180 人中 38 番目)	The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies	<i>Research square</i>			in press
El-Ekiaby M, <u>Tanaka J</u> , van Drimmelen H, Allain JP, Lelie N	Infectivity of hepatitis B virus (HBV) surface antigen (HBsAg) positive plasma with undetectable HBV-DNA: Can HBsAg screening be discontinued in Egyptian blood donors?	<i>Journal of Viral Hepatitis</i>			in press
Akita S, Fujioka M, Akita T, <u>Tanaka J</u> , Masunaga A, Kawahara T	Effects of hand hygiene using 4% chlorhexidine gluconate or natural soap during hand rubbing followed by alcohol-based 1% chlorhexidine gluconate sanitizer lotion in the operating room	<i>Advances in Wound Care</i>	11(1)	1-9	2022
Kikuchi M, Sawabe M, Aoyagi H, Wakae K, Watashi K, Hattori S, Kawabe N, Yoshikawa K, <u>Tanaka J</u> , Muramatsu M, Wakita T, Aizaki H	Development of an intervention system for linkage-to-care and follow-up for hepatitis B and C virus carriers	<i>Hepatology International</i>	16(1)	68-80	2022

Kumada T, Toyoda H, Yasuda S, Ito T, <u>Tanaka J</u>	Mortality of inactive hepatitis B virus carriers in Japan is similar to that of the general population	Hepatology Research	52(1)	81-92	2022
Ouoba S, Okimoto M, Nagashima S, Kitahara Y, Miwata K, Ko K, E B, Sugiyama A, Takahashi K, Sakaguchi T, Takafuta T, <u>Tanaka J</u>	Sequential dynamics of virological and serological changes in the serum of SARS-CoV-2 infected patients	Journal of Medical Virology	94(4)	1734-1737	2022
Inoue M, Hirabayashi M, Abe SK, Katanoda K, Sawada N, Lin Y, Ishihara J, Takachi R, Nagata C, Saito E, Goto A, Ueda K, <u>Tanaka J</u> , Hori M, Matsuda T; the Cancer PAF Japan Collaborators	Burden of cancer attributable to modifiable factors in Japan in 2015	Global Health and Medicine	4(1)	26-36	2022
Imada H, Akita T, Sugiyama A, <u>Tanaka J</u>	Impact of robot-assisted surgery appearance on reduction of annual blood transfusion cases in Japan: application of meta-analysis and NDB open data	Journal of Robotic Surgery	8	1-4	2022
Nobuhara H, Matsugu Y, <u>Tanaka J</u> , Akita T, Ito K	The preventive effects of perioperative oral care on surgical site infections after pancreatic cancer surgery: a retrospective study	Support Care Cancer	30(4)	3337-3344	2022
Toyoda H, Kikuchi K, Tsuruta Y, Hiraoka A, Tsuji K, <u>Tanaka J</u>	Utility of serological tumor biomarkers for surveillance of hepatocellular carcinoma in patients undergoing dialysis	Nephrology, dialysis, transplantation	36(6)	1097-1103	2021
Yoshikawa S, Yoshio S, Yoshida Y, Tsutsui Y, Kawai H, Yamazoe T, Mori T, Osawa Y, Sugiyama M, Iwamoto M, Watashi K, Kawaguchi T, Akita T, <u>Tanaka J</u> , Kikuchi Y, Mizokami M, Oka S, Kanto T, Gatanaga H	Impact of immune reconstitution-induced hepatic flare on HBsAg loss in HBV/HIV-1-coinfecting patients	The Journal of Infectious Diseases	223(12)	2080-2089	2021

Itakura J, Kurosaki M, Setoyama H, Simakami T, Oza N, Korenaga M, Tanaka M, Torimura T, Sakamoto N, Enomoto N, Ueno Y, Kawada N, Kaneko S, Nishiguchi S, Chayama K, <u>Tanaka J</u> , Izumi N, Kanto T	Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis	Journal of Gastroenterology	56(5)	470-478	2021
Kumada T, Toyoda H, Tada T, Yasuda S, Miyake N, <u>Tanaka J</u>	Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels	European journal of gastroenterology and hepatology	32(2)	255-260	2021
Honmyo N, Kobayashi T, Kuroda S, Oshita A, Onoe T, Kohashi T, Fukuda S, Ohmori I, Abe T, Imaoka Y, Akita T, <u>Tanaka J</u> , Ohdan H	A novel model for predicting posthepatectomy liver failure based on liver function and degree of liver resection in patients with hepatocellular carcinoma	HPB	23(1)	134	2021
Tada T, Toyoda H, Kumada T, Kurisu A, Sugiyama A, Akita T, Ohisa M, Aikata H, Miki D, Chayama K, <u>Tanaka J</u>	Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis	Journal of Viral Hepatitis	28(3)	538-547	2021
Nagashima S, Ko K, Yamamoto C, Bunthen E, Ouoba S, Chuon C, Ohisa M, Sugiyama A, Akita T, Hossain MS, Ork V, Mao B, <u>Tanaka J</u>	Prevalence of total hepatitis A antibody among 5 to 7 years old children and their mothers in Cambodia	Scientific Reports	11(1)	4778	2021
Kumada T, Toyoda H, Yasuda S, Miyake N, Ito T, <u>Tanaka J</u>	Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus-related decompensated cirrhosis	Journal of Viral Hepatitis	28(3)	508-516	2021
Razavi H et al. (<u>Tanaka J</u> 含む 193 人中 163 番目)	The case for simplifying and using absolute targets for viral hepatitis elimination goals	Journal of Viral Hepatitis	28(1)	12-19	2021

Kaneyasu Y, Fujiwara H, Nishimura T, Sakurai H, Kazumoto T, Ikushima H, Uno T, Tokumaru S, Harima Y, Gomi H, Toita T, Kita M, Noda S, Takahashi T, Kato S, Hirashima Y, Niibe Y, Nakagawa T, Akita T, <u>Tanaka J</u> , Ohno T, the Working Group of the Gynecological Tumor Committee of the Japanese Radiation Oncology Study Group(JROSG)	A multi-institutional survey of the quality of life after treatment for uterine cervical cancer: A comparison between radical radiotherapy and surgery in Japan	Journal of Radiation Research	62(2)	576-585	2021
Fujimura K, Sugiyama A, Akita T, Ohisa M, Nagashima S, Katayama K, Maeda R, <u>Tanaka J</u>	Screening for M-proteinemia consisting of monoclonal gammopathy of undetermined significance and multiple myeloma for 30 years among atomic bomb survivors in Hiroshima	International Journal of Hematology	113(4)	538-547	2021
Ko K, Nagashima S, E B, Ouoba S, Akita T, Sugiyama A, Ohisa M, Sakaguchi T, Tahara H, Ohge H, Ohdan H, Kubo T, Kishita E, Kuwabara M, Takahashi K, <u>Tanaka J</u>	Molecular characterization and the mutation pattern of SARS-CoV-2 during first and second wave outbreaks in Hiroshima	PLoS One	16(2)	e0246383	2021
Toyoda T, Hiraoka A, Uojima H, Nozaki A, Shimada N, Takaguchi K, Abe H, Atsukawa M, Matsuura K, Ishikawa T, Mikami S, Watanabe T, Itobayashi E, Tsuji K, Arai T, Yasuda S, Chuma M, Senoh T, Tsutsui A, Okubo T, Ehira T, Kumada T, <u>Tanaka J</u>	Characteristics and prognosis of de novo hepatocellular carcinoma after sustained virologic response	Hepatology Communications	5(7)	1290-1299	2021

Kuroda S, Kobayashi T, Tashiro H, Onoe T, Oshita A, Abe T, Kohashi T, Oishi K, Ohmori I, Imaoka Y, <u>Tanaka J</u> , Ohdan H; Hiroshima Surgical Study Group of Clinical Oncology	A multicenter randomized controlled trial comparing administration of antithrombin III after liver resection (HiSCO-05 trial)	Surgery	170(4)		2021
Toyoda H, Yasuda S, Shiota S, Sone Y, Maeda A, Kaneoka Y, Kumada T, <u>Tanaka J</u>	Pretreatment non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of hepatocellular carcinoma development after sustained virologic response in HCV infection	Alimentary Pharmacology and Therapeutics	53(12)		2021
Kumada T, Toyoda H, Yasuda S, Sone Y, Ogawa S, Takeshima K, Tada T, Ito T, Sumida Y, <u>Tanaka J</u>	Prediction of hepatocellular carcinoma by liver stiffness measurements using magnetic resonance elastography after eradicating hepatitis C virus	Clinical and translational gastroenterology	12(4)		2021
Kumada T, Toyoda H, Yasuda S, Tada T, <u>Tanaka J</u> , Chayama K, Johnson PJ, Irving WL	Comparison of the prognosis of decompensated cirrhosis in patients with and without eradication of hepatitis C virus	Infectious Diseases and Therapy	10(2)		2021
Kumada T, Toyoda H, Yasuda S, Tada T, <u>Tanaka J</u>	Usefulness of serial FIB-4 score measurement for predicting the risk of hepatocarcinogenesis after hepatitis C virus eradication	European Journal of Gastroenterology and Hepatology	33		2021
Kumada T, Toyoda H, Yasuda S, Tada T, Ito T, <u>Tanaka J</u>	Long-term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis	Journal of Viral Hepatitis	28(9)		2021
Sugiyama A, Yamashita M, Ko K, Ohisa M, Akita T, Wakita T, <u>Tanaka J</u>	Epidemiological assessment of interventions to eliminate mother-to-child transmission of hepatitis B virus in Japan	GastroHep	3		2021

Maeshige N, Hayashi H, Terashi H, Fujii M, Iwamoto T, Watanabe Yu, Imaoka S, Matsumoto J, Nishikawa M, Takeda N, Mikawa R, Tsuji Y, Higashita R, Ayabe S, Terabe Y, Furukawa M, <u>Tanaka J</u> , Ohura T, Kawabe N	Effect of early rehabilitation on gait, wound and home discharge in lower extremity chronic wound patients: a Japanese multicenter retrospective study	The International Journal of Lower Extremity Wounds		doi:10.1177/15347346211039588	2021
E B, Ko K, Nagashima S, Ouoba S, Hussain Md RA, Sugiyama A, Akita T, Ohisa M, Chuon C, Mao B, Hossain MS, Ork V, <u>Tanaka J</u>	Dried blood spot-based detection of serological profiles of hepatitis B and C infections and their prevalence in Cambodia	GastroHep	3(4)		2021
Toyoda H, Yasuda S, Shiota S, Kumada T, <u>Tanaka J</u>	Lack of hepatitis C virus reinfection in lifetime of Japanese general population with previous hepatitis C virus (HCV) infection successfully treated with anti-HCV therapy	Journal of Infection and chemotherapy	27(11)		2021
Sugiyama A, Kurisu A, Ouoba S, E B, Ko K, Rakhimov A, Hussain Md RA, Akita T, Harakawa T, Sako T, Koshiyama M, <u>Tanaka J</u>	Relationship between drinking frequency and fatty liver prevalence or incidence in Japanese undergoing health checkup in 2008-2019	Liver International	41(12)		2021
Sugimura M, Chimed-Ochir O, Yumiya Y, Ohge H, Shime N, Sakaguchi T, <u>Tanaka J</u> , Takafuta T, Mimori M, Kuwabara M, Asahara T, Kishita E, Kubo T	The Association between Wearing a Mask and COVID-19	International journal of environmental research and public health	18(17)	9131	2021
Ouoba S, Ouedraogo JCRP, Lingani M, E B, Hussain Md RA, Ko K, Nagashima S, Sugiyama A, Akita T, Tinto H, <u>Tanaka J</u>	Epidemiologic profile of hepatitis C virus infection and genotype distribution in Burkina Faso: a systematic review with meta-analysis	BMC Infectious Disease	21	1126	2021
Sugiyama A, Fujii T, Okikawa Y, Sasaki F, Okajima M, Hidaka H, Iwato K, Sato K, Kokubunji A, Takata N, Yamamoto M, <u>Tanaka J</u>	Outcomes of patients who undergo transfusion of fresh frozen plasma: a prospective, observational, multicentre cohort study in Hiroshima, Japan	Journal of Blood Medicine	12(12)	965-973	2021

Lin Y, Wang C, Kikuchi S, Akita T, Tanaka J, Abe SK, Hirabayashi M, Saito E, Hori M, Katanoda K, Matsuda T, Inoue M, the Cancer PAF Japan Collaborators	Burden of cancer attributable to infection in Japan in 2015	Global Health and Medicine	1(2)	63-69	2021
Kumada T, Toyoda H, Yasuda S, Miyake N, Ito T, Tanaka J	Serial changes in FIB-4 score and hepatocarcinogenesis in hepatitis B patients treated with or without nucleot(s)ide analogue therapy	GastroHep	3(1)	37-49	2021
Ko K, Akita T, Satake M, Tanaka J	Epidemiology of viral hepatitis C: Road to elimination in Japan.	Global Health & Medicine	3(5)	262-269	2021
Kumada T, Toyoda H, Yasuda S, Ito T, Tanaka J	Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B	European Journal of Gastroenterology and Hepatology	33(1S Suppl 1)	e898-e904	2021
田中純子、秋田智之	疫学：慢性 C 型肝炎	病原微生物検出情報（月報）	42(1)	3-4	2021
田中純子、秋田智之、菊池勘	疫学の視点からみた C 型肝炎	月間薬事	63(4)	20-25	2021
田中純子、杉山文、栗栖あけみ	てんかんの疫学調査 JMD C データの紹介と NDB 活用の必要性	てんかん診療拠点病院運用の手引き		5-8	2021
永島慎太郎、北原良介、杉山文、沖本真史、E Bunthen、Ouoba Serge、Ko Ko、高蓋寿朗、田中純子	感染症指定医療機関の医療従事者における mRNA COVID-19 ワクチン接種に伴う SARS-CoV-2 IgG 抗体定量値と中和能との関係	感染症学会雑誌			2021
田中純子	総論：日本におけるウイルス性肝炎の疫学と対策	Medical Science Dijest	47(14)	3-5	2021
杉山 文、栗栖あけみ、田中純子	健診受診者集団における NAFLD の疫学	月刊糖尿病	13(7)	20-25	2021
田中純子、秋田智之	C 型肝炎の疫学	消化器内科	3(7)	13-22	2021
田中純子	表紙の画（コラム）	学術の動向	26(9)	3	2021
秋田智之、田中純子	疫学的観点からの COVID-19 流行動態の解析とシミュレーション-広島県データを例として	腎と透析	92(1)	69-79	2021

Inada K, Kaneko S , Kurosaki M, Yamashita K, Kirino S, Osawa L, Hayakawa Y, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Itakura J, Takahashi Y, Tsuchiya K, Nakanishi H, Okamoto R, Izumi N.	Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis.	<i>JGH Open</i>	19;5(9)	1085-1091	2021
Osawa L, Nakanishi H, Kurosaki M, Kirino S, Inada K, Yamashita K, Hayakawa Y, Sekiguchi S, Wang W, Okada M, Higuchi M, Komiyama Y, Takaura K, Takada H, Kaneko S , Maeyashiki C, Tamaki N, Yasui Y, Tsuchiya K, Itakura J, Takahashi Y, Enomoto N, Izumi N.	Plasma Renin Activity Predicts Prognosis and Liver Disease-Related Events in Liver Cirrhosis Patients with Ascites Treated by Tolvaptan.	<i>Dig Dis</i>			2021
Tamaki N, Kurosaki M, Takahashi Y, Itakura Y, Inada K, Kirino S, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Higuchi M, Takaura K, Maeyashiki C, Kaneko S , Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Izumi N.	Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease.	<i>J Gastroenterol Hepatol.</i>	36(10)	2960-2966	2021
Kaneko S , Kurosaki M, Inada K, Kirino S, Hayakawa Y, Yamashita K, Osawa L, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Itakura J, Takahashi Y, Tsuchiya K, Nakanishi H, Izumi N.	Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients.	<i>J Gastroenterol Hepatol.</i>	36(10)	2943-2951	2021

Kaneko S , Kurosaki M, Tsuchiya K, Yasui Y, Inada K, Kirino S, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Itakura J, Takahashi Y, Nakanishi H, Asano D, Irie T, Kawachi Y, Izumi N.	Prognosis of intrahepatic cholangiocarcinoma stratified by albumin-bilirubin grade	Hepato Res.	51(8)	902-908	2021
Kirino S, Tamaki N, Kurosaki M, Inada K, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Higuchi M, Takaura K, Maeyashiki C, Kaneko S , Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Izumi N.	Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment.	J Viral Hepat.	28(5)	787-794	2021
Dultz G, Srikakulam SK, Konetschnik M, Shimakami T, Doncheva NT, Dietz J, Sarrazin C, Biondi RM, Zeuzem S, Tampé R, Kalinina OV, Welsch C.	Epistatic interactions promote persistence of NS3-Q80K in HCV infection by compensating for protein folding instability.	J Biol Chem.	297(3)	101031	2021
島上哲朗, 金子周一	石川県における肝炎ウイルス検診陽性者に対するフォローアップシステム	IASR	42	6-8	2021
Shimakami T, Kaneko S.	Use of information and communication technology in the support of viral hepatitis patients in Japan.	Glob Health Med.	3(5)	314-320	2021

Yamashita T, Koshikawa N, Shimakami T, Terashima T, Nakagawa M, Nio K, Horii R, Iida N, Kawaguchi K, Arai K, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kitao A, Kobayashi S, Takahara S, Imai Y, Yoshimura K, Murayama T, Nakamoto Y, Yoshida E, Yoshimura T, Seiki M, Kaneko S.	Serum Laminin γ 2 Monomer as a Diagnostic and Predictive Biomarker for Hepatocellular Carcinoma.	Hepatology	74(2)	760-775	2021
Hiroko Setoyama, Yasuhito Tanaka, Tatsuya Kanto	Seamless support from screening to anti-HCV treatment and HCC/ decompensated cirrhosis: Subsidy programs for HCV elimination.	Global health & medicine	3 卷 5 号	335-342	2021
Takayuki Tokunaga, Masakuni Tateyama, Kentaro Tanaka, Satoshi Narahara, Hiroki Inada, Sotaro Kurano, Sanae Hayashi, Yoko Yoshimaru, Katsuya Nagaoka, Takehisa Watanabe, Hiroko Setoyama, Motohiko Tanaka, Yasuhito Tanaka	Optimal management of lenvatinib therapy for patients with unresectable hepatocellular carcinoma by balancing the therapeutic effect with the relative dose intensity	Hepatology research	52(1)	105-119	2022
Satoshi Narahara, Takehisa Watanabe, Katsuya Nagaoka, Nahoko Fujimoto, Yoki Furuta, Kentaro Tanaka, Takayuki Tokunaga, Takeshi Kawasaki, Yoko Yoshimaru, Hiroko Setoyama, Kentaro Oniki, Junji Saruwatari, Masakuni Tateyama, Hideaki Naoe, Motohiko Tanaka, Yasuhito Tanaka, Yutaka Sasaki	Clusterin and Related Scoring Index as Potential Early Predictors of Response to Sorafenib in Hepatocellular Carcinoma.	Hepatology communications		doi: 10.1002/hep4 .1872	2021

榎本 大, 日高 勲, 井上 泰輔, 磯田 広 史, 井出 達也, 荒生 祥尚, 内田 義人, 井 上 貴子, 池上 正, 柿崎 暁, 瀬戸山 博 子, 島上 哲朗, 小川 浩司, 末次 淳, 井上 淳, 遠藤 美月, 永田 賢治, 是永 匡紹.	肝疾患診療連携拠点病院に おける肝炎医療コーディネ ーターの現状.	肝臓	62 巻 2 号	96-98	2021
中沢 大, 小高 明日 香, 西井 正造, 武部 貴則	イネープリングファクタ ーが実現する新しい健康	総合健診	48 巻. 6 号	501-510	2021
西井 正造, 武部 貴則	ストリート・メディカル がデザインする新しい医 療	VIVA! ORTHO	No25	8	2022
土肥弘義、考藤達哉	我が国におけるHBワクチ ン使用の現状と展望	臨床消化器内科	35巻2号	199-204	2020
瀬戸山博子、考藤達 哉	効率的な拾い上げと診療の ためのわが国の制度.	消化器・肝臓内 科	8(4)	394-482	2020
瀬戸山博子、考藤達 哉	HCV撲滅に向けた医療行 政の整備	肝臓	62巻4号	220-222	2021
Itakura, J; Kurosaki, M; Setoyama, H; Simakami, T; Oza, N; Korenaga, M; Tanaka, M; Torimura, T; Sakamoto, N; Enomoto, N; Ueno, Y; Kawada, N; Kaneko, S; Nishiguchi, S; Chayama, K; Tanaka, J; Izumi, N; Kanto, T.	Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis.	J. Gastroenterol.	56	470-478	2021
Sakamoto Y, Yoshio S, Doi H, Mori T, Matsuda M, Kawai H, Shimagaki T, Yoshikawa S, Aoki Y, Osawa Y, Yoshida Y, Arai T, Itokawa N, Atsukawa M, Ito T, Honda T, Mise Y, Ono Y, Takahashi Y, Saiura A, Taketomi A, Kanto T* .	Increased frequency of dysfunctional Siglec- 7-CD57+PD-1+ natural killer cells in patients with non-alcoholic fatty liver disease.	Frontiers Immunology			2021

Osawa Y, Yoshio S, Aoki Y, Korenaga M, Imamura M, Oide T, Okawara M, Kawai H, Tsutsui Y, Yoshida Y, Yoshikawa S, Mori T, Yamazoe T, Kanto T* .	Blood angiopoietin-2 predicts liver angiogenesis and fibrosis in hepatitis C patients.	BMC Gastroenterol.	21(1):55.	doi: 10.1186/s12876-021-01633-8.	2021
Yoshio S and Kanto T* .	Macrophages as a source of fibrosis biomarkers for non-alcoholic fatty liver disease.	Immunological Medicine	14	1-26	2021
Yamazoe T, Mori T, Yoshio S, Kanto T* .	Hepatocyte ploidy and pathological mutations in hepatocellular carcinoma: impact on oncogenesis and therapeutics.	Glob Health Med.	2(5)	273-281.	2020
Enomoto H, Ueno Y, Hiasa Y, Nishikawa H, Hige S, Takikawa Y, Taniai M, Ishikawa T, Yasui K, Takaki A, Takaguchi K, Ido A, Kurosaki M, Kanto T , Nishiguchi S;	Japan Etiology of Liver Cirrhosis Study Group in the 54th Annual Meeting of JSH. The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan.	J. Gastroenterol.		doi: 10.1007/s00535-020-01748-x. Online ahead of print. PMID: 33219410	2020
Yoshikawa S, Yoshio S, Yoshida Y, Tsutsui Y, Kawai H, Yamazoe T, Mori T, Osawa Y, Sugiyama M, Iwamoto M, Watashi K, Kawaguchi T, Akita T, Tanaka J, Kikuchi Y, Mizokami M, Oka S, Kanto T , Gatanaga H.	Impact of Immune Reconstitution-induced Hepatic Flare on HBsAg Loss in HBV/HIV-1-Coinfected Patients.	J Infect Dis		doi: 10.1093/infdis/jiaa662	2020

Tahata Y, Hikita H, Mochida S, Kawada N, Enomoto N, Ido A, Yoshiji H, Miki D, Hiasa Y, Takikawa Y, Sakamori R, Kurosaki M, Yatsuhashi H, Tateishi R, Ueno Y, Itoh Y, Yamashita T, <u>Kanto T</u> , Suda G, Nakamoto Y, Kato N, Asahina Y, Matsuura K, Terai S, Nakao K, Shimizu M, Takami T, Akuta N, Yamada R, Kodama T, Tatsumi T, Yamada T, Takehara T.	Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study.	J Gastroenterol		doi: 10.1007/s00535-020-01733-4. Online ahead of print. PMID: 33001338	2020
Polaris Observatory Collaborators.	The case for simplifying and using absolute targets for viral hepatitis elimination goals.	J Viral Hepat.		doi: 10.1111/jvh.13412.	2020
Goto R, Kosai-Fujimoto Y, Yagi S, Kobayashi T, Akamatsu N, Shimamura T, Imura S, Ogiso S, Mizuno S, Takatsuki M, Fukuhara T, <u>Kanto T</u> , Eguchi S, Yanaga K, Ogura Y, Fukumoto T, Shimada M, Hasegawa K, Ohdan H, Uemoto S, Soejima Y, Ikegami T, Yoshizumi T, Taketomi A.	De novo hepatocellular carcinoma in living donor liver grafts: A Japanese multicenter experience.	Hepatol Res	50(12)	1365-1374.	2020
takura J, Kurosaki M, Kakizaki S, Amano K, Nakayama N, Inoue J, Endo T, Marusawa H, Hasebe C, Joko K, Wada S, Akahane T, Koushima Y, Ogawa C, <u>Kanto T</u> , Mizokami M, Izumi N.	Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C.	JHEP Rep	18;2(5)	100138.	2020

Nishikawa K, Kimura K, Kanda Y, Sugiyama M, Kakihana K, Doki N, Ohashi K, Bae SK, Takahashi K, Ishihara Y, Mizuno I, Onishi Y, Onozawa M, Onizuka M, Yamamoto M, Ishikawa T, Inoue K, Kusumoto S, Hashino S, Saito H, <u>Kanto T</u> , Sakamaki H, Mizokami M.	A prospective trial of vaccine to prevent hepatitis B virus reactivation after hematopoietic stem cell transplantation.	Bone Marrow Transplant.		doi: 10.1038/s41409-020-0833-5.	2020
Sakamoto Y, Yoshio S, Doi H, Kawai H, Shimagaki T, Mori T, Matsuda M, Aoki Y, Osawa Y, Yoshida Y, Arai T, Itokawa N, Ito T, Seko Y, Yamaguchi K, Itoh Y, Mise Y, Saiura A, Taketomi A, <u>Kanto T</u> *	Serum soluble Siglec-7 concentration as an indicator of liver macrophage activation and advanced fibrosis in patients with non-alcoholic fatty liver disease.	Hepatology Research	50(4)	466-477.	2020
Yoshikawa S, Yoshio S, Yoshida Y, Tsutsui Y, Kawai H, Yamazoe T, Mori T, Osawa Y, Sugiyama M, Iwamoto M, Watashi K, Kawaguchi T, Akita T, Tanaka J , Kikuchi Y, Mizokami M, Oka S, Kanto T, Gatanaga H	Impact of immune reconstitution-induced hepatic flare on HBsAg loss in HBV/HIV-1-coinfected patients,	The Journal of Infectious Diseases			In press
Tada T, Toyoda H, Kumada T, Kurisu A, Sugiyama A, Akita T, Ohisa M, Aikata H, Miki D, Chayama K, Tanaka J	Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis	Journal of Viral Hepatitis			In press
Honmyo N, Kobayashi T, Kuroda S, Oshita A, Onoe T, Kohashi T, Fukuda S, Ohmori I, Abe T, Imaoka Y, Akita T, Tanaka J , Ohdan H,	A novel model for predicting posthepatectomy liver failure based on liver function and degree of liver resection in patients with hepatocellular carcinoma	HPB			In press

Ko K, Nagashima S, Yamamoto C, Takahashi K, Matsuo J, Ohisa M, Akita T, Matyakubov J, Mirzaev U, Katayama K, Masaki T, Tanaka J	Eighteen-year follow-up cohort study on hepatitis B and C virus infections related long-term prognosis among hemodialysis patients in Hiroshima,	Journal of Medical Virology			In press
Toyoda H, Kikuchi K, Tsuruta Y, Hiraoka A, Tsuji K, Tanaka J.	Utility of serological tumor biomarkers for surveillance of hepatocellular carcinoma in patients undergoing dialysis,	Nephrology, dialysis, transplantation			In press
Nagashima S, Ko K, Yamamoto C, Bunthen E, Ouoba S, Chuon C, Ohisa M, Sugiyama A, Akita T, Hossain MS, Ork V, Mao B, Tanaka J.	Prevalence of total hepatitis A antibody among 5 to 7 years old children and their mothers in Cambodia	Science Report	11(1)	4778	2021
Kumada T, Toyoda H, Yasuda S, Miyake N, Ito T, Tanaka J.	Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus-related decompensated cirrhosis	Journal of Viral Hepatitis	28(3)	508-516	2021
Razavi H et al. (Tanaka J 含む 193人中163番目)	The case for simplifying and using absolute targets for viral hepatitis elimination goals,	Journal of Viral Hepatitis	28(1)	12-19	2021
Kumada T, Toyoda H, Tada T, Yasuda S, Miyake N, Tanaka J	Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels,	European journal of gastroenterology and hepatology,	32(2)	255-260	2021
Kumada T, Toyoda H, Tada T, Yasuda S, Tanaka J	Changes in background liver function in patients with hepatocellular carcinoma over 30 years: Comparison of Child-Pugh classification and albumin bilirubin grade	Liver Cancer	9(5)	518-528	2020
Tada T, Toyoda H, Yasuda S, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J.	Long-term prognosis of liver disease in patients with eradicated chronic hepatitis C virus: an analysis using a Markov chain model,	Hepatology Research	50(8)	936-946	2020

Miki D, Akita T, Kurisu A, Kawaoka T, Nakajima T, Hige S, Karino Y, Toyoda H, Kumada T, Tsuge M, Hiramatsu A, Imamura M, Aikata H, Hayes CN, Honda K, Seike M, Akuta N, Kobayashi M, Kumada H, Tanaka J , Chayama K	PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication,	Journal of Gastroenterology	55(12)	1162-1170	2020
Kumada T, Toyoda H, Yasuda S, Tada T, Ogawa S, Takeshima K, Tanaka J , Chayama K, Johnson PJ	Impact of the introduction of direct-acting anti-viral drugs on hepatocarcinogenesis: a prospective serial follow-up MRI study,	Alimentary Pharmacology and Therapeutics,	52(2)	359-370	2020
Fukami Y, Kaneoka Y, Maeda A, Kumada T, Tanaka J , Akita T, Kubo S, Izumi N, Kadoya M, Sakamoto M, Nakashima O, Matsuyama Y, Kokudo T, Hasegawa K, Yamashita T, Kashiwabara K, Takayama T, Kokudo N, Kudo M, Liver Cancer Study Group of Japan	Liver Resection for Multiple Hepatocellular Carcinomas: A Japanese Nationwide Survey,	Annals of surgery	272(1)	145-154	2020
Yamamoto C, Nagashima S, Chuon C, Ko K, Do SH, Lim O, Hok S, Svay S, Matsuo J, Katayama K, Takahashi K, Tanaka J	Substitution of the CD81 binding site and beta-sandwich area in E2 of HCV in Cambodia	Viruses	12(5)	551-561	2020
Ko K, Takahashi K, Nagashima S, Yamamoto C, Ork V, Sugiyama A, Akita T, Ohisa M, Chuon C, Shafiqul Hossain M, Mao B, Tanaka J	Existence of hepatitis B virus surface protein mutations and other variants: demand for hepatitis B infection control in Cambodia	BMC Infectious Disease	20(1)	305	2020

Nishikawa T, Nagata N, Shimakami T, Shirakura T, Matsui C, Ni Y, Zhuge F, Xu L, Chen G, Nagashimada M, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kaneko S, Ota T.	Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice.	Sci Rep	10(1)	815	2020
Hashiba T, Yamashita T, Okada H, Nio K, Hayashi T, Asahina Y, Hayashi T, Terashima T, Iida N, Takatori H, Shimakami T, Kawaguchi K, Arai K, Sakai Y, Yamashita T, Mizukoshi E, Takamura H, Ohta T, Honda M, Kaneko S.	Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma.	Gastroenterol Hepatol	10(2)	269-285	2020
Terashima T, Honda M, Toyama T, Shimakami T, Shimizu R, Takatori H, Arai K, Kawaguchi K, Kitamura K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Kaneko S.	IL-28B variant as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy.	J Gastroenterol Hepatol.	35(10)	1813-1820	2020
Shimizu Y, Arai K, Yamashita T, Yamashita T, Shimakami T, Kawaguchi K, Kitamura K, Sakai Y, Mizukoshi E, Honda M, Kitao A, Kozaka K, Kobayashi S, Kaneko S.	Direct-Acting Antiviral Agents Reduce the Risk of Malignant Transformation of Hepatobiliary Phase-Hypointense Nodule without Arterial Phase Hyperenhancement to Hepatocellular Carcinoma on Gd-EOB-DPTA-Enhanced Imaging in the Hepatitis C Virus-Infected Liver.	Liver Cancer.	9(3)	261-274	2020
Dultz G, Shimakami T, Schneider M, Murai K, Yamane D, Marion A, Zeitler TM, Stross C, Grimm C, Richter RM, Bäumer K, Yi M, Biondi RM, Zeuzem S, Tampé R, Antes I, Lange CM, Welsch C.	Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors.	J Biol Chem.	295(40)	13862-13874	2020

<p>Kitabayashi J, Shirasaki T, Shimakami T, Nishiyama T, Welsch C, Funaki M, Murai K, Sumiyadorj A, Takatori H, Kitamura K, Kawaguchi K, Arai K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kaneko S.</p>	<p>Upregulation of the Long Non-Coding RNA HULC by Hepatitis C Virus and its Regulation of Viral Replication.</p>	<p><i>J Infect Dis</i></p>		<p>in press</p>	<p>2020</p>
<p>島上哲朗, 金子周一</p>	<p>石川県における肝炎ウイ ルス検診陽性者に対する フォローアップシステム</p>	<p><i>IASR</i></p>	<p>42</p>	<p>6-8</p>	<p>2021</p>